IL2 and acute myeloid leukemia: This article describes a phase I clinical trial of an allogeneic γδ T cell product of the Vγ9Vδ2 subtype, expanded using zoledronic acid and interleukin-2 (IL-2) in patients with relapsed or refractory AML.